These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 18638617

  • 1. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
    Prisant LM.
    Am J Med; 2008 Aug; 121(8 Suppl):S8-15. PubMed ID: 18638617
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Sep; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 6. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K, Miller NH.
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [Abstract] [Full Text] [Related]

  • 7. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 8. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Nov; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 9. Renin-angiotensin system modulation: the weight of evidence.
    Brown B, Hall AS.
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
    [Abstract] [Full Text] [Related]

  • 10. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P, Gentile G, Angeli F, Reboldi G.
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [Abstract] [Full Text] [Related]

  • 11. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Apr; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

  • 12. RAS inhibition in hypertension.
    Ibrahim MM.
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [Abstract] [Full Text] [Related]

  • 13. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V.
    J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
    [Abstract] [Full Text] [Related]

  • 14. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H.
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [Abstract] [Full Text] [Related]

  • 16. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD.
    Rev Cardiovasc Med; 2007 Oct; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [Abstract] [Full Text] [Related]

  • 17. Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction.
    Gradman AH, Papademetriou V.
    Am Heart J; 2009 Jun; 157(6 Suppl):S17-23. PubMed ID: 19450720
    [Abstract] [Full Text] [Related]

  • 18. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E.
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [Abstract] [Full Text] [Related]

  • 19. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E, Muiesan ML.
    J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
    [Abstract] [Full Text] [Related]

  • 20. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C, Wahbi K, Duboc D, Weber S.
    J Cardiovasc Pharmacol Ther; 2011 May; 16(3-4):368-75. PubMed ID: 21193681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.